Part-Time
Social Worker
Memorial Sloan Kettering Cancer Center
10,001+ employees
Cancer treatment, clinical research, and education
Compensation Overview
$59/hr
New York, NY, USA
In Person
Master's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Memorial Sloan Kettering Cancer Center
See people who can refer or advise you
- A Master's degree in Social Work and New York Licensed Clinical Social Worker certification are both required.
- At least 3 years of post-master's work experience in a hospital.
- Strong clinical skills with individuals, families, and groups.
- Excellent written and oral communication skills.
- Proficiency in Microsoft Office applications.
- Conduct screening and biopsychosocial assessment of patients and families to assess their distress and develop ongoing clinical plans.
- Provide clinical interventions and modification of the psychosocial plan, ongoing clinical assessments, advocacy, and assistance with resources for patients and their families.
- Collaborate with an interprofessional team to address ongoing patient needs.
- Assist patients and families in accessing appropriate psychosocial services along the continuum of care.
- Identify the unique needs of the assigned service and develop and implement appropriate interventions and programs.
- Produce quality documentation in the medical record and all written correspondence, and prepare philanthropic budget sheets and other department-related documentation.
- Experience in oncology and/or palliative care in a hospital setting.
- Knowledge of supervisory skills and staff management.
Memorial Sloan Kettering Cancer Center is a leading cancer care and research institution. It provides patient care through Memorial Hospital for Cancer and Allied Diseases and conducts research through the Sloan Kettering Institute, plus education programs. It treats cancer patients with a full range of services (consultations, therapies, and hospital care) and advances new treatments via clinical trials. Treatments and care are delivered by multidisciplinary teams guided by trial results from its research programs. MSK differentiates itself by its integrated model that combines clinical care, translational and basic cancer research, and education, supported by donations, grants, and partnerships with pharma and other research institutions. Its goal is to improve patient outcomes by expanding effective cancer therapies and prevention through rigorous research and high-quality patient care.
Company Size
10,001+
Company Stage
Grant
Total Funding
$90M
Headquarters
New York City, New York
Founded
1884
Get referred to Memorial Sloan Kettering Cancer Center
See people who can refer or advise you
Simplify's Take
What believers are saying
- MSK reported $216.6 million operating surplus and 8.9% cash-flow margin through June 2026.
- Operating revenues rose 11.5% in first-half 2026, driven by higher patient activity.
- MSK launched a July 2026 Phase II cadonilimab trial across the United States.
What critics are saying
- MSK faces Martinez FLSA overtime litigation filed May 1, 2026, in S.D.N.Y.
- MSK faces Rego ADA employment-disability litigation filed May 12, 2026, in S.D.N.Y.
- Adjusted expenses rose 7.0% in first-half 2026, driven by personnel and drug costs.
What makes Memorial Sloan Kettering Cancer Center unique
- MSK ranked No. 2 cancer hospital nationally in U.S. News 2026–27.
- MSK led Akeso’s July 2026 Phase II gastric cancer study with Yelena Janjigian.
- MSK researchers published June 2026 preclinical CAR T work against AML and B-ALL.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Remote Work Options
Company News
GLP-1s and breast cancer: 5 things to know. By: Ella Jeffries Emerging research has linked GLP-1 medicines to a lower risk of breast cancer and better outcomes among people diagnosed with the disease. Here are five findings from studies highlighted in an Aug. 20 Breastcancer.org report: * Lower breast cancer risk. A study of more than 110,000 women ages 45 to 80 with obesity found those taking a GLP-1 had about a 30% lower risk of developing breast cancer. Another study of nearly 230,000 people found GLP-1 users had a 41% lower risk of obesity-related cancers, including breast cancer. * Lower risk of metastasis. A study of more than 10,200 people with stage I, II or III lung, breast, colorectal or liver cancer found those who started GLP-1 medicines after diagnosis had a lower risk of their cancer spreading to other parts of the body. * Fewer treatment complications. Among nearly 62,000 people with breast cancer who underwent a mastectomy, GLP-1 users had a 63% lower risk of lymphedema. * Lower mortality. One study found women with breast cancer taking a GLP-1 were 60% less likely to die from any cause, including breast cancer, over the 10-year follow-up period. Experts cautioned that missing data could have affected the results. * Improved DCIS outcomes. Among people with hormone receptor-positive ductal carcinoma in situ, or DCIS, GLP-1 users had a 74% lower risk of progression to invasive or metastatic cancer. Researchers cautioned that the study had an unexpectedly high number of metastatic cancers, raising questions about the accuracy of the DCIS diagnoses. All of the studies were retrospective, and participants were taking GLP-1s because they had diabetes, obesity or both. So far, studies have not examined cancer risk or outcomes among GLP-1 users without diabetes or obesity. At the Becker's Perioperative Summit, taking place September 14-15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now. Tuesday, August 25 12:00 PM - 1:00 PM CDT Presenter: Jen Anzalone MSN, RN, CNOR, CSSL, NPD-BC, NE-BC, J. Anzalone Consulting Next up in oncology. * Memorial Sloan Kettering back in the black through H1 New York City-based Memorial Sloan Kettering Cancer Center reported operating income of $216.6 million (4.7% operating margin), up from an... By: Andrew Cass * 85 cancer center leadership moves in 2026 From chief financial officers to division chiefs, here are 85 cancer center leadership moves Becker's has covered in 2026: By: Elizabeth Gregerson Friday, August 14th, 2026 * Holyoke Medical Center adds 2 oncologists, expands cancer care Holyoke (Mass.) Medical Center is expanding its oncology and hematology services, adding two physicians and two new office locations to... Becker's staff Wednesday, August 12th, 2026
GRM Information Management and world-class Cancer research and treatment Center expand pathology and document storage relationship. JERSEY CITY, N.J.-(BUSINESS WIRE)-GRM Information Management and Memorial Sloan Kettering Cancer Center are proud to announce an expansion of their existing document and pathology storage relationship. The partnership was originally established in 2020, when GRM began providing storage services for a large portion of MSKCC's pathology blocks and slides that had previously been housed in the facilities of another storage vendor. After five years of delivering quality operations and service, MSKCC recently awarded GRM a multi-year contract that consolidated their entire document and pathology storage collection with GRM. This recent expansion adds tens of thousands of cubic feet of both pathology blocks and slides, as well as physical documents, and the ongoing management and delivery of them to MSKCC's research and clinical operations. GRM President & CEO, Avner Schneur, says, "GRM delivers first-class facilities, superior operations, and continues to define the gold standard for high-quality and consistent customer service." Schneur goes on to add, "And that's why industry-leading organizations like MSKCC are moving to us and consolidating their collections with us." GRM's climate-controlled storage facility, where MSKCC's pathology collection is housed, maintains physical standards and processes that are consistent with HIPAA, CLIA and CAP certification requirements. Additionally, GRM staff who handle and process pathology samples are highly trained and dedicated to servicing GRM's pathology clients. This dedicated segment of GRM's labor force possesses a high level of knowledge of clients and processes, which ultimately results in a nearly error-free environment and speed with processing requests and filling orders for pick-ups and deliveries. As a complement to GRM's high-touch, personal customer service, clients can also utilize GRM's eAccess online inventory management system and dashboard, which serves as the primary means for clients to view inventory and process delivery and pickup requests. The client's capability to request individual blocks and slides for pick-up and delivery is enabled by the barcoding of each sample, which virtually guarantees superior inventory management and traceability. GRM's blocks and slides storage business is a natural extension of GRM's core document storage offering, as well as the company's growing digital healthcare solutions and patient data management solutions. Counting many of the country's largest healthcare organizations as clients, GRM employs their secure cloud-based content services platform, VisualVault, to deliver a broad and growing set of digital data managements and workflow automation solutions that are powered by sophisticated data extraction technologies, robotic process automation (RPA), artificial intelligence (AI) and valuable analytics tools. GRM Information Management is a leading provider of document storage, pathology storage, scanning services and digital information management systems. GRM delivers its clients digital solutions in cooperation with VisualVault, its sister company and cloud-based ECM platform. Serving a diverse base of industries such as healthcare, government, legal, finance and human resources, GRM delivers its clients services such as digital conversion, advanced data capture solutions, document management systems, workflow automation, legacy data archiving, compliance and governance, business process management (BPM) and advanced analytics capabilities, as well as a full suite of document storage, scanning and physical records management services. GRM maintains offices in 15 major metros across the U.S., including Atlanta, Austin, Baltimore, Boston, Chicago, Dallas, Houston, Indianapolis, Los Angeles, Miami, New Jersey/New York, Philadelphia, San Antonio, San Francisco and Washington, D.C. GRM also has facilities in Lima, Peru; Rio de Janeiro, Sao Paulo, Brazil; and Bogota, Medellin and Cali, Colombia. For more information, visit GRM Information Management. August 5th, 2026 August 4th, 2026
U.S. News releases 2026-2027 Best hospital rankings. Aug 4, 2026 Key Takeaways * U.S. News expanded regional and specialty evaluations, adding cancer and cardiovascular regional rankings while increasing Best Regional Hospitals recognition. * Rankings prioritize risk-adjusted mortality, preventable complications, patient experience, and objective outcomes, including patients' ability to return home after treatment. * Psychiatry and rheumatology specialty lists expanded from seven to 17 hospitals, broadening recognition beyond previous national rankings. U.S. News & World Report has published its annual Best Hospitals list for 2026-2027, with the ratings placing emphasis on risk-adjusted mortality rates, preventable complications, and patient experience. A total of 20 hospitals in nine states were named to the Honor Roll, a distinction that covers broad clinical recognition. University of California San Diego Health returned to the list after a yearlong absence, while Mayo Clinic in Florida is new to the list this year. Meet drops. Hear what life with a health condition actually looks like. Now in one app. Built for people living with chronic and rare conditions. The magazine evaluated more than 4,500 hospitals and included 14 adult specialties and 23 procedures and conditions. The list of Best Regional Hospitals also grew to 504 centers, up from 466 last year. "Our core mission is to serve consumers, health care consumers, including patients, their families, referring physicians, and making sure that patients are well informed about both local or regional options for care as well as those that may be farther afield," Ben Harder, U.S. News' managing editor and chief of health analysis, told MedCentral. U.S. News also included four new regional specialty rankings that cover cancer, cardiology, heart and vascular surgery, orthopedics, and rehabilitation. Another 73 hospitals earned Best Regional Hospitals for Community Access honors for delivering critical care to underserved communities. More procedures and conditions rated. The Best Hospitals Specialty rankings and the Procedures & Conditions ratings both draw on empirical data and weigh patient outcomes. This includes risk-adjusted mortality rates, patient experience, and the frequency with which patients are able to return home after treatment. The Procedures & Conditions ratings rest on objective patient care measures. Best Regional Hospitals are those that score well across both systems, according to the criteria detailed in the Procedures & Conditions methodology report. For the 2026-2027 Honor Roll and the specialty and regional rankings, U.S. News drew data from the Centers for Medicare & Medicaid Services, professional organizations, medical specialists, and other sources. Several specialties are highlighted below. Cancer. The list of the top five hospitals specializing in cancer remained unchanged from the previous year's rankings. The University of Texas MD Anderson Cancer Center retained its place as No. 1 in the category, followed by Memorial Sloan Kettering Cancer Center, Dana-Farber Brigham Cancer Center, Mayo Clinic-Rochester, and Massachusetts General Hospital. "This ranking is a tremendous honor, and it reflects our unwavering commitment to continue making progress in our mission to end cancer," said MD Anderson President Peter WT Pisters, MD, in a statement. "We are deeply grateful to everyone who made this recognition possible: our faculty and staff, volunteers, donors, and the patients and families we are honored to serve." U.S. News & World Report added regional cancer rankings this year, extending its evaluations beyond the 50 hospitals named in the national ranking to reach patients who may not live near one of them. "There are others who may not live in a community with one of those hospitals or may not realize that there's great oncology care in their backyard," Harder said. He added that the regional lists use the same scoring and methodology used for hospitals as the national rankings. For more on this year's cancer care center rankings, see Oncology News Central. Cardiology, heart & vascular surgery. The top five in the cardiology category are: NYU Langone Hospitals, Mount Sinai Hospital, Cleveland Clinic, Mayo Clinic-Rochester, New York-Presbyterian Hospital-Columbia and Cornell. Diabetes & endocrinology. The top five in the diabetes & endocrinology category are: Mayo Clinic, New York-Presbyterian Hospital-Columbia and Cornell, Brigham and Women's Hospital, NYU Langone Hospitals, and Northwestern Medicine-Northwestern Memorial Hospital. Gastroenterology & GI surgery. In the gastroenterology & GI surgery category, the magazine recognized the following top five hospitals: Cleveland Clinic, Cedars-Sinai Medical Center, Northwestern Medicine-Northwestern Memorial Hospital, Houston Methodist Hospital, and NYU Langone. Neurology and neurosurgery. The top five in the neurology and neurosurgery category are: NYU Langone Hospitals, Northwestern Medicine-Northwestern Memorial Hospital, UCSF Health-UCSF Medical Center, New York-Presbyterian Hospital-Columbia and Cornell, and Mayo Clinic. Psychiatry. This year's psychiatry specialty hospital list grew to 17 centers, up from seven hospitals last year. The top five in this specialty were: Massachusetts General Hospital, McLean Hospital, New York-Presbyterian Hospital-Columbia and Cornell, Johns Hopkins Hospital, and Resnick Neuropsychiatric Hospital at UCLA. Pulmonology & lung surgery. In order, the top five-ranked pulmonology and lung surgery hospitals are: UCSF Health-UCSF Medical Center, NYU Langone Hospitals, Mayo Clinic, Northwestern Medicine-Northwestern Memorial Hospital, and UCLA Ronald Reagan Medical Center. Rheumatology. The number of centers specializing in rheumatology also grew from seven in 2025-2026 to 17 in the most recent rankings. The top five-ranked hospitals are: Johns Hopkins Hospital, Cleveland Clinic, N.Y.-Presby. U. Hosp. of Columbia and Cornell, Mayo Clinic, and Brigham and Women's Hospital.
Memorial Sloan Kettering Cancer Center ranked top Cancer Center in the Northeast and in New York metropolitan area, second in nation, and first in urology care by U.S News and World Report. Tuesday, August 4, 2026 Memorial Sloan Kettering Cancer Center (MSK) has again been recognized among the nation's very best, earning the distinction as the top cancer center in the Northeast and in the New York metropolitan area, the #2 hospital for cancer care in the country, and the #1 hospital in the nation for urology care in the 2026-27 U.S. News & World Report Best Hospitals rankings. MSK has held its place among the nation's top two cancer hospitals and remained the leading cancer center in the Northeast since the rankings were established more than 35 years ago. "Being named the top cancer center in the Northeast and New York metropolitan area, and among the nation's leading cancer hospitals, is both an honor and a responsibility," said Selwyn M. Vickers, MD, FACS, President and CEO of MSK. "This recognition reflects the extraordinary people of MSK. Every day, our physicians, researchers, nurses, and staff advance cancer care with one goal in mind: improving the lives of patients and families. Together, we are working to end cancer for life." This latest recognition comes during a remarkable period of innovation and achievement. Over the past year, MSK earned national and global recognition for excellence in patient care, nursing, innovation, and workplace culture. In 2025, the U.S. Food and Drug Administration (FDA) approved 10 drugs based on clinical trials in which MSK played a pivotal role. Additionally, MSK earned its third Magnet(R) designation for nursing excellence and received Press Ganey's Guardian of Excellence Award for patient experience. MSK was also recognized by Forbes for the eighth consecutive year as one of America's Best Large Employers and as the nation's top cancer center to work for, and it was named one of Fast Company's Top 10 Best Workplaces for Innovators. For the fourth consecutive year, MSK secured USNWR's #1 national ranking in urology care, underscoring its leadership in the field. MSK's multidisciplinary urology team brings together experts in surgery, medical oncology, radiation oncology, radiology, pathology, and nursing to deliver highly personalized care while advancing innovative treatments that improve outcomes and preserve quality of life. In addition, MSK's gastroenterology and GI surgery services were ranked #25. The U.S. News & World Report rankings evaluate hospitals using a range of measures, including clinical outcomes, patient safety, nursing excellence, and reputation among board-certified physician specialists. Together, these honors underscore MSK's long-standing leadership in transforming cancer care and advancing hope for patients around the world.
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives. 3 August 2026 NEW YORK, NY, August 3, 2026 - Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center. "We are delighted to welcome Greg to Royalty Pharma," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Greg's experience in licensing and drug development, combined with his investing background, makes him uniquely suited to deepen our engagement with the scientific community. We see an exciting opportunity to support innovators as they navigate today's funding challenges. Increasingly, academic institutions are at the forefront of discovering novel targets, advancing our understanding of disease biology and mechanisms of action, and pioneering new therapeutic modalities that give rise to cutting-edge medicines. By helping them unlock new funding solutions, we can advance their missions while expanding our access to groundbreaking innovation, creating true win-win partnerships." "Royalty Pharma has long played a foundational role in connecting breakthrough science to the capital needed to advance important innovation," said Greg Raskin. "I am excited to join in this new role, where I will partner with universities and non-profits, reflecting Royalty Pharma's long-standing commitment to supporting academic science." Greg Raskin Biography Prior to joining Royalty Pharma, Greg spent more than a decade at Memorial Sloan Kettering Cancer Center, most recently as Senior Vice President, Technology Development, where he led biotechnology startup efforts, technology transfer, monetization and business development. Earlier in his career, Greg was a Vice President at AllianceBernstein, where he led healthcare and life sciences investing for the firm's venture capital fund. Previously, he served as a biotech analyst at Baker Brothers Investments and as a management consultant at McKinsey & Company, where he primarily worked with pharmaceutical and biotech companies. Greg received his M.D. from Yale School of Medicine and a B.A. in molecular biophysics and biochemistry from Yale College. He currently serves as a Lecturer in the Department of Economics at both Stanford University and Yale University, where he teaches courses on the economics and science of drug development. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-6772 [email protected]